Pharmacokinetics and Tolerability Evaluation of Human Coagulation Recombinant Factor VIII ($GreenGene^{TM}$) in Hemophilia A Patients

혈우병 A형 환자에서 재조합 혈액응고인자 VIII (그린진주$^{TM}$)의 내약성 및 약동학적 특성에 관한 연구

  • Han, Hye-Kyung (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Shin, Kwang-Hee (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Paik, Sang-Hoon (GC-Research Center, Green Cross Corporation) ;
  • Chung, Jae-Yong (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Lim, Kyoung-Soo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Cho, Joo-Youn (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Yoon, Seo-Hyun (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital)
  • 한혜경 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과) ;
  • 신광희 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과) ;
  • 백상훈 (주식회사 녹십자 종합연구소) ;
  • 정재용 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과) ;
  • 임경수 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과) ;
  • 조주연 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과) ;
  • 윤서현 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과) ;
  • 신상구 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과) ;
  • 장인진 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과) ;
  • 유경상 (서울대학교 의과대학 약리학교실, 서울대학교병원 임상약리학과)
  • Received : 2011.11.29
  • Accepted : 2011.12.28
  • Published : 2011.12.30

Abstract

Background: $GreenGene^{TM}$ (Green Cross Corp.) is a recombinant clotting factor VIII which is used for hemophilia A. This study aimed to investigate the pharmacokinetics and safety profiles of 25 IU/kg and 50 IU/kg of $GreenGene^{TM}$ in Korean hemophilia A patients. Methods: A dose-block randomized, single-blind, active drug-controlled, single and multiple dose, parallel-group study was conducted with 16 hemophilia A patients (25 IU/kg: 50 IU/kg = 8:8). They received $GreenGene^{TM}$ or $GreenMono^{TM}$(active control) intravenously on day 1 and every other day from day 4 to 10. FVIII:C (Factor VIII procoagulant activity) was measured to determine the pharmacokinetics (PK) at baseline and up to 48 hours for single and multiple administration. PK parameters were determined using noncompartmental methods. Results: The maximum concentration ($C_{max}$) and the area under the concentration-time curve ($AUC_{0-48}$) of the $GreenGene^{TM}$ 25 IU/kg ($mean{\pm}SD$) were $59.00{\pm}19.26$ % and $774.40{\pm}380.13%{\cdot}h$ respectively, while those of 50 IU/kg were $131.50{\pm}39.81$ % and $1462.44{\pm}397.09%{\cdot}h$ after single administration. The $C_{max}$ and $AUC_{0-48}$ in steady state of the $GreenGene^{TM}$ 25 IU/kg were $68.17{\pm}22.75$ % and $863.30{\pm}334.40%{\cdot}h$, while those of 50 IU/kg were $147.17{\pm}18.47$ % and $1820.08{\pm}704.42%{\cdot}h$. No serious adverse event was observed. Conclusion: The $GreenGene^{TM}$ to hemophilia A patients appeared to be well tolerated within range of 25-50 IU/kg. The PK parameters of factor VIII showed dose-independent manner with 25 IU/kg and 50 IU/kg dose ranges.

Keywords

Acknowledgement

Supported by : (주)녹십자

References

  1. White GC, 2nd, Shoemaker CB. Factor VIII gene and hemophilia A. Blood, 1989;73(1):1-12.
  2. Oldenburg J, El-Maarri O. New insight into the molecular basis of hemophilia A. Int J Hematol, 2006;83(2):96-102. https://doi.org/10.1532/IJH97.06012
  3. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet, 2001;40(11):815-832. https://doi.org/10.2165/00003088-200140110-00003
  4. Gringeri A, Muca-Perja M, Mangiafico L, von Mackensen S. Pharmacotherapy of haemophilia A. Expert Opin Biol Ther, 2011;11(8):1039-1053. https://doi.org/10.1517/14712598.2011.570006
  5. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Hemophilia, 2008;14 Suppl 3:10-18.
  6. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Hemophilia, 2003;9(1):38-49. https://doi.org/10.1046/j.1365-2516.2003.00708.x
  7. Pipe SW. Recombinant clotting factors. Thromb Haemost, 2008;99(5):840-850.
  8. Goodeve AC, Rosen S, Verbruggen B. Haemophilia A and von Willebrand's disease. Haemophilia, 2010;16 Suppl 5:79-84. https://doi.org/10.1111/j.1365-2516.2010.02303.x
  9. Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost, 2010;104(5):931-940. https://doi.org/10.1160/TH10-03-0151
  10. Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost, 2004;2(7):1047-1054. https://doi.org/10.1046/j.1538-7836.2004.00710.x
  11. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood, 2003;102(7):2358-2363. https://doi.org/10.1182/blood-2003-03-0941
  12. Martinowitz U, Bjerre J, Brand B, Klamroth R, Misgav M, Morfini M, et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE(R))--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Hemophilia, 2011;17(6):854-859. https://doi.org/10.1111/j.1365-2516.2011.02495.x
  13. Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol, 2009;65(10):989-998. https://doi.org/10.1007/s00228-009-0676-x